Chi-Yuan Hsu1,2, Kathleen D Liu3, Jingrong Yang2, David V Glidden4, Thida C Tan2, Leonid Pravoverov5, Sijie Zheng2,5, Alan S Go3,2,4,6. 1. Division of Nephrology, Department of Medicine, and hsuchi@medicine.ucsf.edu. 2. Division of Research, Kaiser Permanente Northern California, Oakland, California. 3. Division of Nephrology, Department of Medicine, and. 4. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. 5. Kaiser Permanente Oakland Medical Center, Oakland, California; and. 6. Departments of Medicine (Nephrology), Health Research and Policy, Stanford University, Palo Alto, California.
Abstract
BACKGROUND AND OBJECTIVES: How to best medically manage patients who survived hospitalized AKI is unclear. Use of renin-angiotensin system blockers in this setting may increase risk of recurrent AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a cohort study of 10,242 members of an integrated health care delivery system in Northern California who experienced AKI and survived a hospitalization between January 1, 2006 and December 31, 2013. All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior. New receipt and time-updated exposure of ACE-Is/ARBs was identified on the basis of dispensed prescriptions found in outpatient health plan pharmacy databases. The main outcome of interest was subsequent episode of hospitalized AKI after discharge from an initial index hospitalization complicated by AKI. Recurrent AKI episode was defined using acute changes in serum creatinine concentrations. Marginal structural models were used to adjust for baseline and potential time-dependent confounders. RESULTS: Forty-seven percent of the study population had a documented eGFR<60 ml/min per 1.73 m2 or documented proteinuria before hospitalization. With a median of 3 (interquartile range, 1-5) years of follow-up, 1853 (18%) patients initiated use of ACE-Is/ARBs and 2124 (21%) patients experienced recurrent AKI. Crude rate of recurrent AKI was 6.1 (95% confidence interval [95% CI], 5.9 to 6.4) per 100 person-years off ACE-Is/ARBs and 5.7 (95% CI, 4.9 to 6.5) per 100 person-years on ACE-Is/ARBs. In marginal structural causal inference models that adjusted for baseline and potential time-dependent confounders, exposure to ACE-I/ARB use was not associated with higher incidence of recurrent AKI (adjusted odds ratio, 0.71; 95% CI, 0.45 to 1.12). CONCLUSIONS: In this study of AKI survivors without heart failure, new use of ACE-I/ARB therapy was not independently associated with increased risk of recurrent hospitalized AKI.
BACKGROUND AND OBJECTIVES: How to best medically manage patients who survived hospitalized AKI is unclear. Use of renin-angiotensin system blockers in this setting may increase risk of recurrent AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a cohort study of 10,242 members of an integrated health care delivery system in Northern California who experienced AKI and survived a hospitalization between January 1, 2006 and December 31, 2013. All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior. New receipt and time-updated exposure of ACE-Is/ARBs was identified on the basis of dispensed prescriptions found in outpatient health plan pharmacy databases. The main outcome of interest was subsequent episode of hospitalized AKI after discharge from an initial index hospitalization complicated by AKI. Recurrent AKI episode was defined using acute changes in serum creatinine concentrations. Marginal structural models were used to adjust for baseline and potential time-dependent confounders. RESULTS: Forty-seven percent of the study population had a documented eGFR<60 ml/min per 1.73 m2 or documented proteinuria before hospitalization. With a median of 3 (interquartile range, 1-5) years of follow-up, 1853 (18%) patients initiated use of ACE-Is/ARBs and 2124 (21%) patients experienced recurrent AKI. Crude rate of recurrent AKI was 6.1 (95% confidence interval [95% CI], 5.9 to 6.4) per 100 person-years off ACE-Is/ARBs and 5.7 (95% CI, 4.9 to 6.5) per 100 person-years on ACE-Is/ARBs. In marginal structural causal inference models that adjusted for baseline and potential time-dependent confounders, exposure to ACE-I/ARB use was not associated with higher incidence of recurrent AKI (adjusted odds ratio, 0.71; 95% CI, 0.45 to 1.12). CONCLUSIONS: In this study of AKI survivors without heart failure, new use of ACE-I/ARB therapy was not independently associated with increased risk of recurrent hospitalized AKI.
Authors: Itziar Navarro; Rafael Poveda; Joan Torras; Alberto M Castelao; Josep M Grinyó Journal: Nephrol Dial Transplant Date: 2007-09-21 Impact factor: 5.992
Authors: Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Jerry H Gurwitz; David J Magid; David H Smith; Robert J Goldberg; David D McManus; Larry A Allen; Jane S Saczynski; Micah L Thorp; Grace Hsu; Sue Hee Sung; Alan S Go Journal: Am J Med Date: 2013-03-14 Impact factor: 4.965
Authors: Edward D Siew; Sharidan K Parr; Khaled Abdel-Kader; Svetlana K Eden; Josh F Peterson; Nisha Bansal; Adriana M Hung; James Fly; Ted Speroff; T Alp Ikizler; Michael E Matheny Journal: J Am Soc Nephrol Date: 2015-08-11 Impact factor: 10.121
Authors: Chi-Yuan Hsu; Vernon M Chinchilli; Steven Coca; Prasad Devarajan; Nasrollah Ghahramani; Alan S Go; Raymond K Hsu; T Alp Ikizler; James Kaufman; Kathleen D Liu; Chirag R Parikh; W Brian Reeves; Mark Wurfel; Michael Zappitelli; Paul L Kimmel; Edward D Siew Journal: JAMA Intern Med Date: 2020-03-01 Impact factor: 21.873
Authors: Edward D Siew; Kathleen D Liu; John Bonn; Vernon Chinchilli; Laura M Dember; Timothy D Girard; Tom Greene; Adrian F Hernandez; T Alp Ikizler; Matthew T James; Kevin Kampschroer; Jeffrey B Kopp; Marla Levy; Paul M Palevsky; Neesh Pannu; Chirag R Parikh; Michael V Rocco; Samuel A Silver; Heather Thiessen-Philbrook; Ron Wald; Yining Xie; Paul L Kimmel; Robert A Star Journal: J Am Soc Nephrol Date: 2020-09-10 Impact factor: 10.121
Authors: Gurmukteshwar Singh; Yirui Hu; Steven Jacobs; Jason Brown; Jason George; Maria Bermudez; Kevin Ho; Jamie A Green; H Lester Kirchner; Alex R Chang Journal: Kidney360 Date: 2021-07-13
Authors: Anitha Vijayan; Emaad M Abdel-Rahman; Kathleen D Liu; Stuart L Goldstein; Anupam Agarwal; Mark D Okusa; Jorge Cerda Journal: Clin J Am Soc Nephrol Date: 2021-08-30 Impact factor: 10.614
Authors: Sandeep Brar; Kathleen D Liu; Alan S Go; Raymond K Hsu; Vernon M Chinchilli; Steven G Coca; Amit X Garg; Jonathan Himmelfarb; T Alp Ikizler; James Kaufman; Paul L Kimmel; Chirag R Parikh; Edward D Siew; Lorraine B Ware; Hui Zeng; Chi-Yuan Hsu Journal: Clin J Am Soc Nephrol Date: 2020-12-03 Impact factor: 8.237
Authors: Dennis G Moledina; Olivia Belliveau; Yu Yamamoto; Tanima Arora; Kyle A Carey; Matthew Churpek; Melissa Martin; Caitlin M Partridge; Sherry G Mansour; Chirag R Parikh; Jay L Koyner; F Perry Wilson Journal: Am J Kidney Dis Date: 2020-10-17 Impact factor: 8.860
Authors: Marco Trevisan; Edouard L Fu; Yang Xu; Kitty Jager; Carmine Zoccali; Friedo W Dekker; Juan Jesus Carrero Journal: Clin Kidney J Date: 2020-12-14